You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial
|
|---|---|
| Published in |
Lancet Oncology, November 2014
|
| DOI | 10.1016/s1470-2045(14)71017-4 |
| Pubmed ID | |
| Authors |
Glen A Kennedy, Antiopi Varelias, Slavica Vuckovic, Laetitia Le Texier, Kate H Gartlan, Ping Zhang, Gethin Thomas, Lisa Anderson, Glen Boyle, Nicole Cloonan, Justine Leach, Elise Sturgeon, Judy Avery, Stuart D Olver, Mary Lor, Ashish K Misra, Cheryl Hutchins, A James Morton, Simon TS Durrant, Elango Subramoniapillai, Jason P Butler, Cameron I Curley, Kelli P A MacDonald, Siok-Keen Tey, Geoffrey R Hill |
X Demographics
The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 32% |
| India | 2 | 11% |
| Spain | 1 | 5% |
| Mexico | 1 | 5% |
| Australia | 1 | 5% |
| Unknown | 8 | 42% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 53% |
| Scientists | 6 | 32% |
| Practitioners (doctors, other healthcare professionals) | 3 | 16% |
Mendeley readers
The data shown below were compiled from readership statistics for 114 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Australia | 1 | <1% |
| Unknown | 112 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 23 | 20% |
| Student > Master | 12 | 11% |
| Student > Ph. D. Student | 9 | 8% |
| Other | 7 | 6% |
| Student > Bachelor | 7 | 6% |
| Other | 24 | 21% |
| Unknown | 32 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 48 | 42% |
| Biochemistry, Genetics and Molecular Biology | 11 | 10% |
| Agricultural and Biological Sciences | 5 | 4% |
| Immunology and Microbiology | 5 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
| Other | 6 | 5% |
| Unknown | 37 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 40. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 April 2021.
All research outputs
#1,021,912
of 25,371,288 outputs
Outputs from Lancet Oncology
#1,235
of 6,881 outputs
Outputs of similar age
#11,221
of 269,845 outputs
Outputs of similar age from Lancet Oncology
#18
of 164 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,881 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.2. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 269,845 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 164 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.